Re-treatment with SLT after initial treatment failure does not reduce IOP

Article

Two treatments with selective laser trabeculoplasty (SLT) in the same area of the trabecular meshwork (TM) do not significantly affect IOP, compared with two SLT treatments in differing areas, according to a recently published study.

Two treatments with selective laser trabeculoplasty (SLT) in the same area of the trabecular meshwork (TM) do not significantly affect IOP, compared with two SLT treatments in differing areas, according to a recent study published in Graefe's Archive for Clinical and Experimental Ophthalmology.

For this prospective, randomized clinical trial, patients with primary open-angle or pseudoexfoliation glaucoma were initially treated with SLT over 180° in the lower half of the trabecular meshwork (SLT 1). A total of 40 patients chosen for re-treatment with SLT were included in the study, and were randomized to either SLT 2 in the same, previously treated area of the TM, or to SLT 2 in the upper untreated area of the TM. IOPs were measured at pre-treatment, 2 hours, 1 month, 3 months and 6 months after SLT 2.

At baseline, no significant between-group differences existed in age, gender, pseudoexfoliation, glaucoma, time between SLT 1 and SLT 2, IOP before SLT, or IOP before SLT 2. After the study was completed, there were no significant differences in IOP between the groups after SLT 2 at 2 hours (t-test, P = 0.65), 1 month (t-test, P = 0.60), 3 months (t-test, P = 0.42), or 6 months (t-test, P = 0.66).

To access this study, go to the journal's website here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.